Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.
Intellia Therapeutics’ in vivo CRISPR therapy, lonvoguran ziclumeran (lonvo-z), reduced hereditary angioedema (HAE) attacks by 87% in a Phase III trial, with 62% of patients attack-free over six ...
– Announcement follows recent U.S. government award from the Biomedical Advanced Research and Development Authority supporting development of VIR-2482 – SAN FRANCISCO, Oct. 18, 2022 (GLOBE NEWSWIRE) - ...
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial This randomized phase II/III trial enrolled patients with SCLC, no brain ...
Current guidelines recommend 5 to 7 days of broad-spectrum antibiotic prophylaxis for upper gastrointestinal bleeding in patients with cirrhosis. In a systematic review and meta-analysis, shorter ...
Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...
Intellia Therapeutics will seek U.S. approval for its in vivo CRISPR therapy lonvo-z after a Phase III trial in hereditary angioedema showed an 87% reduction in attacks versus placebo. The one-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results